Unicycive Therapeutics, Inc. (UNCY) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Unicycive Therapeutics, Inc.

UNCY

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

91M

Biotechnology

0.75USD

0.07 ( 10.70%)

Pre-market 0.63$

-0.13 (-16.79%)

Market Closed (as of Jun 16, 20:00 EDT)

Relative Strenght

Volume Buzz

82%

Earning Acce

Dist 52w H.

31%

Overview Chart

Quote Panel

Updated June 17, 2025

1W 19.75 % 1M 24.47 % 3M 26.82 % 1Y 16.80 %

Key Metrics

Market Cap
90.99M
Shares Outstanding
120.63M
Share in Float
100.03M
Dividende
0

Earning Date
No Data
Price Target
0.7543
Average Volume
2.77M
Beta
2.001

Range
0.202-1.1
Industry
Biotechnology
Website
https://www.unicycive.com
Sector
Healthcare

Quote Panel

Updated June 17, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

78.18x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-0.6

EPS

How UNCY compares to sector?

P/E Ratio

Fundamentals

Relative Strength

UNCY

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

UNCY

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$368M

NaN%

2026-Revenue

$1.59

3279%

2026-EPS

$74M

1020%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Piper Sandler

initialise

Previous: Not converted

2024-04-04

Now: Overweight

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.29
vs -0.24

Q3.23

N/A

-0.13
vs -0.37

Q4.23

N/A

-0.16
vs -0.35

Q1.24

N/A

-0.27
vs -0.29

Q2.24

N/A

-0.15
vs -0.29

Q3.24

+100%

NA
vs -0.13

Q4.24

N/A

-0.16
vs -0.16

Q1.25

N/A

NA
vs -0.27

Q2.25

N/A

-0.07
vs -0.15

Q3.25

N/A

-0.07
vs NA

Sales Growth

YoY

Current

Estimates

Q1.23

675K vs NA

Q2.23

NA vs NA

Q3.23

-100%

NA vs 951K

Q4.23

-271000.00 vs NA

Q1.24

-100%

NA vs 675K

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

+100%

NA vs -271000

Q1.25

NA vs NA

Q3.25

2.4M vs NA

Return on Equity

QoQ

Q2.23

-56%

-0.56
vs -2.39

Q3.23

-128%

-1.28
vs -0.56

Q4.23

+205%

2.05
vs -1.28

Q1.24

+86%

0.86
vs 2.05

Q2.24

+31%

0.31
vs 0.86

Q3.24

-15%

-0.15
vs 0.31

Q4.24

-290%

-2.90
vs -0.15

Q1.25

+5%

0.05
vs -2.90

Institutionnal Ownership

QoQ

Q2.23

15
vs 13

15%

Q3.23

16
vs 15

Q4.23

16
vs 16

Q1.24

23
vs 16

44%

Q2.24

24
vs 23

Q3.24

28
vs 24

17%

Q4.24

31
vs 28

11%

Q1.25

29
vs 31

-6%

Earnings Growth

Latest News

globenewswire.com

6 hours ago

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

globenewswire.com

7 hours ago

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at Upcoming Investor Conferences

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

globenewswire.com

7 hours ago

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

globenewswire.com

7 hours ago

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Company Description

0.75USD

N/A

0.00x

78.18x

0.0

0.0%

$-0.6

$368M

$1.59

$74M

Earnings Growth

Latest News

$368M

$1.59

$74M

Company Description

0.75USD

N/A

0.00x

78.18x

0.0

0.0%

$-0.6